Topadur Pharma develops locally acting small molecules for wound healing and fibrosis, including TOP-N53, which is in phase 2a. The non-profit DEBRA Research is investing to fund a preclinical programme against dystrophic epidermolysis bullosa.
- Announced on
- Round
- Undisclosed round
- Amount
- Amount not disclosed
- Location
- canton of Zurich
- Sector
- Biotech & life sciences
Investors
- DEBRA Research
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic